David Frank

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation
    Erik A Nelson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Oncotarget 2:518-24. 2011
  2. ncbi request reprint Targeting transcription factors for cancer therapy
    David A Frank
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medical Oncology, Mayer 522B, 44 Binney Street, Boston, MA 02115, USA
    IDrugs 12:29-33. 2009
  3. ncbi request reprint STAT3 as a central mediator of neoplastic cellular transformation
    David A Frank
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Lett 251:199-210. 2007
  4. pmc B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues
    D A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 100:3140-8. 1997
  5. ncbi request reprint The treatment and outcome of cancer patients with thromboses on central venous catheters
    D A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Thromb Thrombolysis 10:271-5. 2000
  6. ncbi request reprint Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling
    D A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Med 5:444-7. 1999
  7. pmc STAT signaling in the pathogenesis and treatment of cancer
    D A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Med 5:432-56. 1999
  8. ncbi request reprint Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis
    James V Alvarez
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 3:1045-50. 2004
  9. ncbi request reprint Reciprocal effects of STAT5 and STAT3 in breast cancer
    Sarah R Walker
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Mol Cancer Res 7:966-76. 2009
  10. ncbi request reprint STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1
    Traci E Battle
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    Blood 102:3016-24. 2003

Collaborators

Detail Information

Publications33

  1. pmc A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation
    Erik A Nelson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Oncotarget 2:518-24. 2011
    ..Data derived from these studies can then provide key insights into mechanisms of STAT signal transduction, as well as inform the rational design of targeted therapeutic strategies for cancer patients...
  2. ncbi request reprint Targeting transcription factors for cancer therapy
    David A Frank
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medical Oncology, Mayer 522B, 44 Binney Street, Boston, MA 02115, USA
    IDrugs 12:29-33. 2009
    ....
  3. ncbi request reprint STAT3 as a central mediator of neoplastic cellular transformation
    David A Frank
    Department of Medical Oncology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Lett 251:199-210. 2007
    ..Since normal cells are relatively tolerant of interruption in STAT3 signaling, these findings suggest that STAT3 may also be an excellent target for the molecular therapy of cancer...
  4. pmc B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues
    D A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 100:3140-8. 1997
    ..In summary, the constitutive serine phosphorylation of STAT1 and STAT3 is present in all CLL samples tested to date, although the physiologic significance of this modification remains to be determined...
  5. ncbi request reprint The treatment and outcome of cancer patients with thromboses on central venous catheters
    D A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Thromb Thrombolysis 10:271-5. 2000
    ..A prospective trial to evaluate these approaches may be worthwhile so that the use of unnecessary procedures may be avoided in this patient population...
  6. ncbi request reprint Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling
    D A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Med 5:444-7. 1999
    ..Thus, STAT1 may be a useful target in the development of new immunosuppressive and antineoplastic agents...
  7. pmc STAT signaling in the pathogenesis and treatment of cancer
    D A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Med 5:432-56. 1999
    ..Thus, elucidation of cellular and biochemical processes in tumors has enhanced our understanding of the pathogenesis of malignancies and may provide the basis for significant advances in therapy...
  8. ncbi request reprint Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis
    James V Alvarez
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Biol Ther 3:1045-50. 2004
    ..Analysis of these targets can provide insight into mechanisms of neoplastic transformation, and may shed light on new strategies for targeted therapy...
  9. ncbi request reprint Reciprocal effects of STAT5 and STAT3 in breast cancer
    Sarah R Walker
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Mol Cancer Res 7:966-76. 2009
    ....
  10. ncbi request reprint STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1
    Traci E Battle
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    Blood 102:3016-24. 2003
    ..This study implicates STAT transcription factors as important mediators of Bryostatin 1-induced differentiation of CLL cells and could possibly lead to improved therapeutic approaches for the treatment of CLL...
  11. ncbi request reprint Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy
    Doris Germain
    Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Clin Cancer Res 13:5665-9. 2007
    ..Thus, elucidating the functions of STAT3 and developing agents to inhibit this protein remain important scientific and clinical challenges...
  12. ncbi request reprint Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors
    James V Alvarez
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 65:5054-62. 2005
    ..Finally, we showed that STAT3 is required for the expression of these genes in a breast cancer cell line. Taken together, these results identify a cohort of STAT3 targets that may mediate its role in oncogenesis...
  13. pmc Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells
    Ellen Weisberg
    Department of Medical Oncology Hematologic Neoplasia, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 6:e25351. 2011
    ..Thus, there is a need for identification of molecular mechanisms of clinical resistance to these drugs. In response, we characterized MOLM13 AML cell lines made resistant to two structurally-independent FLT3 inhibitors...
  14. pmc Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
    Heidi Greulich
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS Med 2:e313. 2005
    ..The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations and their relationship to drug sensitivity have not been described...
  15. ncbi request reprint StAT signaling in cancer: insights into pathogenesis and treatment strategies
    David A Frank
    Department of Adult Oncology, Dana Farber Cancer Institute, Departments of Medicine, Harvard Medical School and Brigham and Women s Hospital, Boston, MA, USA
    Cancer Treat Res 115:267-91. 2003
  16. ncbi request reprint Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification
    Erik A Nelson
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 279:54724-30. 2004
    ....
  17. pmc A SnoN-Ccd1 pathway promotes axonal morphogenesis in the mammalian brain
    Yoshiho Ikeuchi
    Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 29:4312-21. 2009
    ..These findings define a novel SnoN-Ccd1 link that promotes axonal growth in the mammalian brain, with important implications for axonal development and regeneration...
  18. ncbi request reprint Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model
    Yuki Ishii
    Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Natl Cancer Inst 98:1238-47. 2006
    ..One potential mechanism for this association involves signal transducer and activator of transcription 3 (STAT3)...
  19. ncbi request reprint In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response
    Traci E Battle
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:2166-72. 2003
    ....
  20. pmc Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness
    Nuria de la Iglesia
    Department of Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 28:5870-8. 2008
    ..These studies suggest that STAT3 activation or IL8 inhibition may have potential in patient-tailored treatment of PTEN-deficient brain tumors...
  21. ncbi request reprint IL-6-induced survival of colorectal carcinoma cells is inhibited by butyrate through down-regulation of the IL-6 receptor
    Hanna Yuan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Carcinogenesis 25:2247-55. 2004
    ..These experiments indicate that IL-6 may play an important role in the pathogenesis of colorectal cancers, and that butyrate may exert its protective effect by specifically blocking IL-6-induced signaling events...
  22. pmc IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
    Emmanuel Zorn
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:1571-9. 2006
    ..Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo...
  23. ncbi request reprint Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
    James V Alvarez
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 66:3162-8. 2006
    ..Thus, STAT3 is a critical mediator of the oncogenic effects of somatic EGFR mutations and targeting STAT3 may be an effective strategy for treating tumors characterized by these mutations...
  24. ncbi request reprint The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
    Traci E Battle
    Department of Medical Oncology, Mayer 522B, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:690-7. 2005
    ..These data indicate that honokiol is a potent inducer of apoptosis in B-CLL cells and should be examined for further clinical application either as a single agent or in combination with other anticancer agents...
  25. pmc Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3
    Bo Xu
    Department of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mol Cell Biol 23:3918-28. 2003
    ..Both of these events are important steps in IL-13-induced 15-LO expression in human monocytes...
  26. ncbi request reprint Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Leuk Res 28:139-47. 2004
    ..Larger studies are indicated to determine optimal timing of STAT1 assessment, and if changes in STAT1 represent an in vivo indicator of response to purine analog therapy...
  27. ncbi request reprint A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 29:1009-18. 2005
    ..These studies suggest that the IL-4R, on B-CLL cells, can serve as a unique molecular target for directing cytotoxic agents in the therapy of B-CLL...
  28. ncbi request reprint Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells
    Hajime Isomoto
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 42:1329-38. 2005
    ..In conclusion, we have directly demonstrated a STAT3 regulatory element in the Mcl-1 promoter. Downregulation of Mcl-1 transcription by inhibiting this cascade is a potential strategy for the treatment of this cancer...

Research Grants7

  1. STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
    David Frank; Fiscal Year: 1999
    ..As a result of these experiments, we plan to discern the role of STATs in the abnormal growth of CLL cells, and to identify targets for novel and specific therapies. ..
  2. STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
    David Frank; Fiscal Year: 2000
    ..As a result of these experiments, we plan to discern the role of STATs in the abnormal growth of CLL cells, and to identify targets for novel and specific therapies. ..
  3. STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
    David Frank; Fiscal Year: 2001
    ..As a result of these experiments, we plan to discern the role of STATs in the abnormal growth of CLL cells, and to identify targets for novel and specific therapies. ..
  4. STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
    David Frank; Fiscal Year: 2002
    ..As a result of these experiments, we plan to discern the role of STATs in the abnormal growth of CLL cells, and to identify targets for novel and specific therapies. ..
  5. STAT SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
    David Frank; Fiscal Year: 2003
    ..As a result of these experiments, we plan to discern the role of STATs in the abnormal growth of CLL cells, and to identify targets for novel and specific therapies. ..
  6. High Throughput Screening for Modulators of STAT5 (RMI)
    David Frank; Fiscal Year: 2004
    ..The ultimate goal is the development of compounds that will act as targeted therapies for human cancers. ..
  7. STAT3 in the Pathogenesis and Treatment of Pancreatic Cancer
    David Frank; Fiscal Year: 2007
    ..We will test these drugs to determine whether they can be prototypes for a novel targeted form of therapy for this disease. ..